Patents by Inventor Pingyu Zhong
Pingyu Zhong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11912761Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.Type: GrantFiled: January 15, 2021Date of Patent: February 27, 2024Assignee: Agency for Science, Technology and ResearchInventors: Cheng-I Wang, Angeline Goh, Siok Ping Yeo, Alessandra Rosa Mortellaro, Subhra Kumar Biswas, Florent Ginhoux, Pingyu Zhong
-
Patent number: 11780913Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.Type: GrantFiled: October 1, 2020Date of Patent: October 10, 2023Assignee: Agency for Science, Technology and ResearchInventors: Cheng-I Wang, Angeline Goh, Siok Ping Yeo, Alessandra Rosa Mortellaro, Subhra Kumar Biswas, Florent Ginhoux, Pingyu Zhong
-
Patent number: 11702471Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.Type: GrantFiled: January 15, 2021Date of Patent: July 18, 2023Assignee: Agency for Science, Technology and ResearchInventors: Cheng-I Wang, Angeline Goh, Siok Ping Yeo, Alessandra Rosa Mortellaro, Subhra Kumar Biswas, Florent Ginhoux, Pingyu Zhong
-
Publication number: 20210155685Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.Type: ApplicationFiled: January 15, 2021Publication date: May 27, 2021Applicant: Agency for Science, Technology and ResearchInventors: Cheng-I WANG, Angeline GOH, Siok Ping YEO, Alessandra Rosa MORTELLARO, Subhra Kumar BISWAS, Florent GINHOUX, Pingyu ZHONG
-
Publication number: 20210155686Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.Type: ApplicationFiled: January 15, 2021Publication date: May 27, 2021Applicant: Agency for Science, Technology and ResearchInventors: Cheng-I WANG, Angeline GOH, Siok Ping YEO, Alessandra Rosa MORTELLARO, Subhra Kumar BISWAS, Florent GINHOUX, Pingyu ZHONG
-
Patent number: 10919962Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.Type: GrantFiled: November 15, 2018Date of Patent: February 16, 2021Assignee: Agency for Science, Technology and ResearchInventors: Cheng-I Wang, Angeline Goh, Siok Ping Yeo, Alessandra Rosa Mortellaro, Subhra Kumar Biswas, Florent Ginhoux, Pingyu Zhong
-
Publication number: 20210024627Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.Type: ApplicationFiled: October 1, 2020Publication date: January 28, 2021Applicant: Agency for Science, Technology and ResearchInventors: Cheng-I WANG, Angeline GOH, Siok Ping YEO, Alessandra Rosa MORTELLARO, Subhra Kumar BISWAS, Florent GINHOUX, Pingyu ZHONG
-
Publication number: 20190144535Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.Type: ApplicationFiled: November 15, 2018Publication date: May 16, 2019Applicant: Agency for Science, Technology and ResearchInventors: Cheng-l Wang, Angeline Goh, Siok Ping Yeo, Alessandra Mortellaro, Subhra Kumar Biswas, Florent Ginhoux, Pingyu Zhong
-
Patent number: 10167335Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.Type: GrantFiled: February 13, 2013Date of Patent: January 1, 2019Assignee: Agency for Science, Technology and ResearchInventors: Cheng-I Wang, Angeline Goh, Siok Ping Yeo, Alessandra Mortellaro, Subhra Kumar Biswas, Florent Ginhoux, Pingyu Zhong
-
Patent number: 8957194Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: GrantFiled: May 8, 2012Date of Patent: February 17, 2015Assignee: Merck Sharpe & Dohme Corp.Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Timothy McCabe, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Pixley, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Publication number: 20150037248Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.Type: ApplicationFiled: February 13, 2013Publication date: February 5, 2015Applicant: Agency for Science, Technology and ResearchInventors: Cheng-I Wang, Angeline Goh, Siok Ping Yeo, Alessandra Mortellaro, Subhra Kumar, Florent Ginhoux, Pingyu Zhong
-
Patent number: 8877900Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: GrantFiled: October 29, 2010Date of Patent: November 4, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Peter Peizhi Luo, Kevin Caili Wangr, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon, Sujata Sharma, Jon Condra, Jun Lu, Gopalakrishnan Parthasarathy, Stephen Soisson, Noel Byrne
-
Patent number: 8802827Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: GrantFiled: October 29, 2010Date of Patent: August 12, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Peter Peizhi Luo, Kevin Caili Wang, Pingyu Zhong, Mark Hsieh, Yan Li, Xinwei Wang, Feng Dong, Andrei Golosov, Yan Ni, Weirong Wang, Laurence B. Peterson, Rose Cubbon
-
Publication number: 20140220027Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: April 14, 2014Publication date: August 7, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder Pixley, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Publication number: 20140121123Abstract: The invention provides methods of introducing diversity into antibody molecules comprising introducing or substituting at least one amino acid sequence in the CDR of the target antibody together with at least one amino acid in the FW region spanning the 3 amino acid adjoining the CRD on each side. The resulting diverse antibodies with variant CDRs and FW region sequences comprising diverse amino acid sequences are also described. These polypeptides regions, herein referred to as 3+CDR3+, that form the gist of the invention contribution described herein provide a flexible and simple source of sequence diversity that can be used as a source for expressing and identifying diverse antibodies or antigen binding polypeptides. Libraries comprising a plurality of these polypeptides are also provided. In addition, methods of and compositions for generating and using these polypeptides and libraries are provided.Type: ApplicationFiled: October 24, 2011Publication date: May 1, 2014Inventors: Kevin Caili Wang, Yan Li, Mark Hsieh, Xinwei Wang, Xinwei Wang, Feng Dong, Peizhi (Peter) Luo, Pingyu Zhong
-
Patent number: 8697070Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: GrantFiled: May 8, 2012Date of Patent: April 15, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Pixley, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Patent number: 8637435Abstract: The present invention provides expression vectors and helper display vectors which can be used in various combinations as vector sets for display of polypeptides on the outer surface of eukaryotic host cells. The expression vector of the invention can be used alone for soluble expression without having to change or reengineer the display vectors. The display systems of the invention are particularly useful for displaying a genetically diverse repertoire or library of polypeptides on the surface of yeast cells, and mammalian cells.Type: GrantFiled: November 14, 2008Date of Patent: January 28, 2014Assignee: Merck Sharp & Dohme Corp.Inventors: Kevin Caili Wang, Peter Peizhi Luo, Pingyu Zhong, Jian Wang
-
Publication number: 20130071379Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: May 8, 2012Publication date: March 21, 2013Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Timothy McCabe, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peter Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Publication number: 20120329679Abstract: The present invention provides expression vectors and helper display vectors which can be used in various combinations as vector sets for display of polypeptides on the outer surface of eukaryotic host cells. The expression vector of the invention can be used alone for soluble expression without having to change or reengineer the display vectors. The display systems of the invention are particularly useful for displaying a genetically diverse repertoire or library of polypeptides on the surface of yeast cells, and mammalian cells.Type: ApplicationFiled: March 23, 2012Publication date: December 27, 2012Applicant: MERCK SHARP & DOHME CORP.Inventors: Kevin Caili Wang, Peter Peizhi Luo, Pingyu Zhong, Jian Wang
-
Publication number: 20120301461Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: May 8, 2012Publication date: November 29, 2012Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li